Pharmacological interventions in human aging
Ageing Res Rev. 2024 Feb 1:102213. doi: 10.1016/j.arr.2024.102213. Online ahead of print.ABSTRACTPharmacological interventions are emerging as potential avenues of alleviating age-related disease. However, the knowledge of ongoing clinical trials as they relate to aging and pharmacological interventions is dispersed across a variety of mediums. In this review we summarize 136 age-related clinical trials that have been completed or are ongoing. Furthermore, we establish a database that describe the trials (AgingDB, www.agingdb.com) keeping track of the previous and ongoing clinical trials, alongside their outcomes. The aim ...
Source: Ageing Research Reviews - February 3, 2024 Category: Genetics & Stem Cells Authors: Michael Petr Frida Matiyevskaya Brenna Osborne Magnus Berglind Simon Reves Bin Zhang Michael Ben Ezra Lina Maria Carmona Marin Muhammad Farraz Syahzha Marta Cort és Mediavilla Guido Keijzers Daniela Bakula Garik Mkrtchyan Morten Scheibye-Knudsen Source Type: research
Breaking the links between ageism and health: An integrated perspective
Ageing Res Rev. 2024 Feb 1;95:102212. doi: 10.1016/j.arr.2024.102212. Online ahead of print.ABSTRACTAgeism refers to prejudice, stereotypes or discrimination based on a person's actual or perceived chronological age. While ageism can affect people at all stages of the human lifespan, ageism against older adults has emerged as the most pervasive and potentially harmful. Much is now understood about how ageism can impact older people's health and wellbeing via structural, organisational, and provider level biases that threaten the provision of equitable and ethical healthcare. Negative attitudes about age and ageing also con...
Source: Ageing Research Reviews - February 2, 2024 Category: Genetics & Stem Cells Authors: Julie D Henry Sarah P Coundouris Matthew R Nangle Source Type: research
Psychedelics for Alzheimer's Disease-Related Dementia: Unveiling Therapeutic Possibilities and Pathways
Ageing Res Rev. 2024 Jan 31:102211. doi: 10.1016/j.arr.2024.102211. Online ahead of print.ABSTRACTPsychedelics have traditionally been used for spiritual and recreational purposes, but recent developments in psychotherapy have highlighted their potential as therapeutic agents. These compounds, which act as potent 5-hydroxytryptamine (5HT) agonists, have been recognized for their ability to enhance neural plasticity through the activation of the serotoninergic and glutamatergic systems. However, the implications of these findings for the treatment of neurodegenerative disorders, particularly dementia, have not been fully ex...
Source: Ageing Research Reviews - February 2, 2024 Category: Genetics & Stem Cells Authors: Jitendra Kumar Sinha Anchal Trisal Shampa Ghosh Saurabh Gupta Krishna Kumar Singh Sung Soo Han Madhumita Mahapatra Mosleh Mohammad Abomughaid Ali M Abomughayedh Abdulmajeed G Almutary Danish Iqbal Rakesh Bhaskar Abhishek Kumar Singh Prabhu Chandra Mishra Source Type: research
An update on new-age potential biomarkers for Parkinson's disease
Ageing Res Rev. 2024 Feb;94:102208. doi: 10.1016/j.arr.2024.102208. Epub 2024 Jan 29.ABSTRACTParkinson's disease (PD) is a progressive neurodegenerative disorder that deals with dopaminergic deficiency in Substantia nigra pars compact (SNpc) region of the brain. Dopaminergic deficiency manifests into motor dysfunction. Alpha-synuclein protein aggregation is the source for inception of the pathology. Motor symptoms include rigidity, akinesia, tremor and gait dysfunction. Pre-motor symptoms are also seen in early stage of the disease; however, they are not distinguishable. Lack of early diagnosis in PD pathology poses a majo...
Source: Ageing Research Reviews - January 31, 2024 Category: Genetics & Stem Cells Authors: Ritu Soni Kirti Mathur Jigna Shah Source Type: research
Impact of micronutrients and nutraceuticals on cognitive function and performance in Alzheimer's disease
Ageing Res Rev. 2024 Feb 1;95:102210. doi: 10.1016/j.arr.2024.102210. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is a major global health problem today and is the most common form of dementia. AD is characterized by the formation of β-amyloid (Aβ) plaques and neurofibrillary clusters, leading to decreased brain acetylcholine levels in the brain. Another mechanism underlying the pathogenesis of AD is the abnormal phosphorylation of tau protein that accumulates at the level of neurofibrillary aggregates, and the areas most affected by this pathological process are usually the cholinergic neurons in cortical, su...
Source: Ageing Research Reviews - January 31, 2024 Category: Genetics & Stem Cells Authors: Lorenza Guarnieri Francesca Bosco Antonio Leo Rita Citraro Ernesto Palma Giovambattista De Sarro Vincenzo Mollace Source Type: research
New insight on the possible role of statins in Vascular Parkinsonism: A need for presumptive therapy
In conclusion, statins can prevent and treat VP by inhibiting inflammatory and oxidative stress disorders, mitigating of white matter hyperintensities and improving of neuronal signaling pathways. Additional preclinical, clinical trials and prospective studies are warranted in this regard.PMID:38286334 | DOI:10.1016/j.arr.2024.102209 (Source: Ageing Research Reviews)
Source: Ageing Research Reviews - January 29, 2024 Category: Genetics & Stem Cells Authors: Hayder M Al-Kuraishy Majid S Jabir Ali I Al-Gareeb Ali K Albuhadily Source Type: research
Neural alterations underlying executive dysfunction in Parkinson's disease: A systematic review and coordinate-based meta-analysis of functional neuroimaging studies
Ageing Res Rev. 2024 Jan 26;95:102207. doi: 10.1016/j.arr.2024.102207. Online ahead of print.ABSTRACTParkinson's Disease's (PD) neuropsychological profile is often characterized by altered performance in executive functions (EF) tasks, with a remarkable impact on patients' quality of life. To date, the available neuroimaging literature lacks conclusive evidence about neural patterns underlying EF deficits in PD. Here, we aimed to synthesize the results of PET/fMRI studies examining the differences in brain activation between PD patients and controls during EF tasks, focusing on the three main EF sub-components: cognitive f...
Source: Ageing Research Reviews - January 28, 2024 Category: Genetics & Stem Cells Authors: Eleonora Arrigoni Paola Antoniotti Virginia Bellocchio Laura Veronelli Massimo Corbo Alberto Pisoni Source Type: research
PARP1 at the crossroad of cellular senescence and nucleolar processes
Ageing Res Rev. 2024 Feb;94:102206. doi: 10.1016/j.arr.2024.102206. Epub 2024 Jan 24.ABSTRACTSenescent cells that occur in response to telomere shortening, oncogenes, extracellular and intracellular stress factors are characterized by permanent cell cycle arrest, the morphological and structural changes of the cell that include the senescence-associated secretory phenotype (SASP) and nucleoli rearrangement. The associated DNA lesions induce DNA damage response (DDR), which activates the DNA repair protein - poly-ADP-ribose polymerase 1 (PARP1). This protein consumes NAD+ to synthesize ADP-ribose polymer (PAR) on its own pr...
Source: Ageing Research Reviews - January 26, 2024 Category: Genetics & Stem Cells Authors: Kinga Ko łacz Agnieszka Robaszkiewicz Source Type: research
The proteinopenia hypothesis: Loss of A β < sub > 42 < /sub > and the onset of Alzheimer's Disease
Ageing Res Rev. 2023 Dec;92:102112. doi: 10.1016/j.arr.2023.102112. Epub 2023 Oct 28.ABSTRACTThe dominant protein-lowering strategy in Alzheimer's Disease (AD) has failed to provide a clinically-meaningful treatment for patients. We hypothesize that the loss of functional, soluble Aβ42 during the process of aggregation into amyloid is more detrimental to the brain than the corresponding accrual of insoluble amyloid.PMID:38270185 | DOI:10.1016/j.arr.2023.102112 (Source: Ageing Research Reviews)
Source: Ageing Research Reviews - January 25, 2024 Category: Genetics & Stem Cells Authors: Alberto J Espay Karl Herrup Kasper P Kepp Timothy Daly Source Type: research
Epigenetic reprogramming as a key to reverse ageing and increase longevity
Ageing Res Rev. 2024 Jan 23;95:102204. doi: 10.1016/j.arr.2024.102204. Online ahead of print.ABSTRACTThe pursuit for the fountain of youth has long been a fascination amongst scientists and humanity. Ageing is broadly characterized by a cellular decline with increased susceptibility to age-related diseases, being intimately associated with epigenetic modifications. Recently, reprogramming-induced rejuvenation strategies have begun to greatly alter longevity research not only to tackle age-related defects but also to possibly reverse the cellular ageing process. Hence, in this review, we highlight the major epigenetic chang...
Source: Ageing Research Reviews - January 25, 2024 Category: Genetics & Stem Cells Authors: Beatriz Pereira Francisca P Correia In ês A Alves Margarida Costa Mariana Gameiro Ana P Martins Jorge A Saraiva Source Type: research
Understanding the mechanisms of disease modifying effects of aerobic exercise in people with Alzheimer's disease
Ageing Res Rev. 2024 Feb;94:102202. doi: 10.1016/j.arr.2024.102202. Epub 2024 Jan 23.ABSTRACTAlzheimer's disease (AD) is a very disabling disease. Pathologically, it is characterized by the presence of amyloid plaques and neurofibrillary tangles in the brain that results in neurodegeneration. Its clinical manifestations include progressive memory impairment, language decline and difficulty in carrying out activities of daily living (ADL). The disease is managed using interventions such as pharmacological interventions and aerobic exercise. Use of aerobic exercise has shown some promises in reducing the risk of developing A...
Source: Ageing Research Reviews - January 25, 2024 Category: Genetics & Stem Cells Authors: Auwal Abdullahi Thomson Wl Wong Shamay Sm Ng Source Type: research
Harnessing two-dimensional nanomaterials for diagnosis and therapy in neurodegenerative diseases: Advances, challenges and prospects
Ageing Res Rev. 2024 Feb;94:102205. doi: 10.1016/j.arr.2024.102205. Epub 2024 Jan 24.ABSTRACTNeurodegenerative diseases (NDDs) are specific brain disorders characterized by the progressive deterioration of different motor activities as well as several cognitive functions. Current conventional therapeutic options for NDDs are limited in addressing underlying causes, delivering drugs to specific neuronal targets, and promoting tissue repair following brain injury. Due to the paucity of plausible theranostic options for NDDs, nanobiotechnology has emerged as a promising field, offering an interdisciplinary approach to create ...
Source: Ageing Research Reviews - January 25, 2024 Category: Genetics & Stem Cells Authors: Samir Kumar Beura Abhishek Ramachandra Panigrahi Pooja Yadav Irene Palacio Elena Casero Carmen Quintana Jyoti Singh Manoj Kumar Singh Jose A Mart ín Gago Sunil Kumar Singh Source Type: research
In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review
Ageing Res Rev. 2024 Feb;94:102197. doi: 10.1016/j.arr.2024.102197. Epub 2024 Jan 22.ABSTRACTPositron emission tomography (PET) with radiotracers that bind to synaptic vesicle glycoprotein 2 A (SV2A) enables quantification of synaptic density in the living human brain. Assessing the regional distribution and severity of synaptic density loss will contribute to our understanding of the pathological processes that precede atrophy in neurodegeneration. In this systematic review, we provide a discussion of in vivo SV2A PET imaging research for quantitative assessment of synaptic density in various dementia conditions: amnestic...
Source: Ageing Research Reviews - January 24, 2024 Category: Genetics & Stem Cells Authors: Malouke Visser John T O'Brien Elijah Mak Source Type: research
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
CONCLUSION: Although it is yet to be determined which is more effective between lithium or lecanemab or donanemab, lithium may be more effective than aducanumab. Aducanumab, lecanemab and donanemab do not appear to differ in their effectiveness on cognitive function. Low-dose lithium may be safer than aducanumab, lecanemab and donanemab.PMID:38253184 | DOI:10.1016/j.arr.2024.102203 (Source: Ageing Research Reviews)
Source: Ageing Research Reviews - January 22, 2024 Category: Genetics & Stem Cells Authors: Itsuki Terao Wakako Kodama Source Type: research
The interference between SARS-COV-2 and Alzheimer's disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic
Ageing Res Rev. 2024 Feb;94:102195. doi: 10.1016/j.arr.2024.102195. Epub 2024 Jan 18.ABSTRACTCoronavirus disease 2019 (COVID-19) has infected over 700 million people, with up to 30% developing neurological manifestations, including dementias. However, there is a lack of understanding of common molecular brain markers causing Alzheimer's disease (AD). COVID-19 has etiological cofactors with AD, making patients with AD a vulnerable population at high risk of experiencing more severe symptoms and worse consequences. Both AD and COVID-19 have upregulated several shared kinases, leading to the repositioning of kinase inhibitors...
Source: Ageing Research Reviews - January 20, 2024 Category: Genetics & Stem Cells Authors: Heba M Mansour Source Type: research
